Kar Murat, Altıntoprak Niyazi, Muluk Nuray Bayar, Ulusoy Seckin, Bafaqeeh Sameer Ali, Cingi Cemal
ENT Clinics, Kumluca State Hospital, Antalya, Turkey.
ENT Clinics, Tuzla State Hospital, Istanbul, Turkey.
Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4111-4117. doi: 10.1007/s00405-016-3983-8. Epub 2016 Mar 16.
We assessed the use of antileukotrienes for treating adenotonsillar hypertrophy. We reviewed the current literature on the anatomy of adenotonsillar tissue, adenotonsillar hypertrophy/hyperplasia (and the associated pathophysiology and symptoms), and the effects of antileukotrienes used to treat adenotonsillar hypertrophy. Leukotrienes (LTs) are inflammatory mediators produced by a number of cell types, including mast cells, eosinophils, basophils, macrophages, and monocytes. There are several types (e.g., LTA4, LTB4, LTC4, LTD4, and LTE4). By competitive binding to the cysLT1 receptor, LT-receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast block the effects of cySHLTs, improving the symptoms of some chronic respiratory diseases. High numbers of LT receptors have been found in the tonsils of children with obstructive sleep apnea. Antileukotrienes reduce the apnea-hypopnea index and adenotonsillar inflammation. Antileukotrienes may be useful for children with adenotonsillar hypertrophy due to their anti-inflammatory effects, which help to reduce adenotonsillar inflammation.
我们评估了抗白三烯药物用于治疗腺样体扁桃体肥大的情况。我们回顾了有关腺样体扁桃体组织的解剖结构、腺样体扁桃体肥大/增生（以及相关的病理生理学和症状），以及用于治疗腺样体扁桃体肥大的抗白三烯药物的作用的当前文献。白三烯（LTs）是由多种细胞类型产生的炎症介质，包括肥大细胞、嗜酸性粒细胞、嗜碱性粒细胞、巨噬细胞和单核细胞。有几种类型（例如，LTA4、LTB4、LTC4、LTD4和LTE4）。通过与半胱氨酰白三烯1（cysLT1）受体竞争性结合，孟鲁司特、扎鲁司特和普仑司特等LT受体拮抗剂药物可阻断半胱氨酰白三烯（cySHLTs）的作用，改善一些慢性呼吸道疾病的症状。在患有阻塞性睡眠呼吸暂停的儿童扁桃体中发现了大量的LT受体。抗白三烯药物可降低呼吸暂停低通气指数和腺样体扁桃体炎症。由于其抗炎作用有助于减轻腺样体扁桃体炎症，抗白三烯药物可能对患有腺样体扁桃体肥大的儿童有用。
